Endocrinology Drugs Market Report 2026

Endocrinology Drugs Market Overview

• Endocrinology Drugs market size has reached to $26.2 billion in 2025 • Expected to grow to $26.42 billion in 2030 at a compound annual growth rate (CAGR) of 0.2% • Growth Driver: Surge In Prevalence Of Endocrine Diseases Driving Market Growth Due To Increased Need For Long-Term Therapeutic Management • Market Trend: Expanding Access Through Authorized Generic GLP‑1 Receptor Agonists • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Endocrinology Drugs Market?

Endocrinology drugs refer to pharmaceutical treatments specifically designed to manage and regulate disorders related to the endocrine system, which includes glands such as the thyroid, pancreas, and adrenal glands. These drugs are used for the treatment of conditions like diabetes, thyroid disorders, growth hormone deficiencies, and hormonal imbalances, helping to restore normal hormonal levels and improve the overall functioning of the endocrine system. The main indications for endocrinology drugs include hyperthyroidism, hypothyroidism, diabetes, polycystic ovarian syndrome, growth hormone disorders, pituitary gland disorders, and others. Hyperthyroidism is characterized by excessive production of thyroid hormones, leading to symptoms such as weight loss, rapid heartbeat, and anxiety. The primary therapy areas include diabetes drugs, thyroid hormone disorder drugs, human growth hormone, testosterone replacement therapy, and other therapy areas. They are distributed through various channels, such as hospital pharmacies, online pharmacies, and retail pharmacies, and are used by various end users, including hospitals, ambulatory surgical centers, and others.

What Is The Endocrinology Drugs Market Growth Forecast?

The endocrinology drugs market size is expected to see marginal growth in the next few years. It will grow to $26.42 billion in 2030 at a compound annual growth rate (CAGR) of 0.2%. The growth in the forecast period can be attributed to aging population, rising lifestyle-related disorders, growth in diabetes drug innovation, expansion of online pharmacies, increasing endocrine screening rates. Major trends in the forecast period include rising long-term management of chronic endocrine disorders, increasing use of combination hormonal therapies, growing demand for diabetes and thyroid disorder drugs, expansion of outpatient endocrine care, increased focus on hormone replacement therapies.

Global Endocrinology Drugs Market Segmentation

1) By Indication: Hyperthyroidism, Hypothyroidism, Diabetes, Polycystic Ovarian Syndrome, Growth Hormone Disorders, Pituitary Gland Disorders, Other Indications 2) By Therapy Area: Diabetes Drugs, Thyroid Hormone Disorder Drugs, Human Growth Hormone, Testosterone Replacement Therapy, Other Therapy Areas 3) By Distribution Channel: Hospital pharmacies, Online Pharmacies, Retail pharmacies 4) By End User: Hospitals, Ambulatory Surgical Centers, Other End Users Subsegments: 1) By Hyperthyroidism: Antithyroid Medications, Radioactive Iodine Therapy, Beta Blockers 2) By Hypothyroidism: Levothyroxine-based Medications, Liothyronine-based Medications, Combination Hormonal Therapies 3) By Diabetes: Insulin Therapies, Oral Antidiabetic Drugs (OADs), GLP-1 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors 4) By Polycystic Ovarian Syndrome (PCOS): Oral Contraceptives, Metformin, Clomiphene Citrate, Anti-Androgens 5) By Growth Hormone Disorders: Recombinant Human Growth Hormone (rhGH), Growth Hormone Secretagogues, Growth Hormone Receptor Antagonists 6) By Pituitary Gland Disorders: Somatostatin Analogs, Gonadotropins, Dopamine Agonists 7) By Other Indications: Adrenal Gland Disorders, Osteoporosis, Parathyroid Disorders, Male Hormonal Imbalances

What Is The Driver Of The Endocrinology Drugs Market?

The rising prevalence of endocrine diseases is expected to propel the growth of the endocrinology drugs market going forward. Endocrine diseases are disorders that impact the endocrine system, causing imbalances in hormone production or regulation, which can interfere with normal bodily functions. The rising prevalence of endocrine diseases can be attributed to several factors, including lifestyle changes, an aging population, and improved diagnosis, which have all contributed to the increased recognition and incidence of these conditions. Endocrinology drugs help manage endocrine diseases by regulating hormone levels, addressing glandular dysfunction, and restoring hormonal balance to alleviate symptoms and improve overall health outcomes. For instance, in February 2025, according to World Health Organization, a Switzerland-based United Nations agency focused on global public health, polycystic ovary syndrome (PCOS) affects an estimated 6 to 13% of reproductive-aged women, with up to 70% of affected women remaining undiagnosed worldwide. Therefore, the rising prevalence of endocrine diseases is driving growth in the endocrinology drugs industry.

Key Players In The Global Endocrinology Drugs Market

Major companies operating in the endocrinology drugs market are Johnson & Johnson Inc., Merck & Co. Inc., AbbVie Inc., Bayer Aktiengesellschaft, Novartis International AG, Sanofi S.A., AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Biocon Limited, Boehringer Ingelheim International GmbH, Mylan N.V., Sandoz International GmbH, Ipsen Pharma, Ferring Pharmaceuticals Inc., Endocrine Pharma Private Limited

Global Endocrinology Drugs Market Trends and Insights

Major companies operating in the endocrinology drugs market are focusing on product innovation and formulation such as authorized generics of GLP‑1 receptor agonists, to increase patient access, reduce treatment costs, and enhance market competitiveness while maintaining safety and efficacy profiles. These strategies enable wider availability of key diabetes and obesity therapies and support adherence to chronic treatment regimens. For instance, in June 2024, Teva Pharmaceuticals, a US-based pharmaceutical company, announced the launch of an authorized generic of Victoza (liraglutide) injection 1.8 mg in the United States. The authorized generic offers the same formulation and therapeutic profile as the branded product, providing clinicians and patients with a cost-effective option for managing type 2 diabetes and obesity. This launch reflects the broader market trend toward enhancing access to essential endocrinology therapies through generic and authorized generic formulations, helping to meet growing demand for diabetes management solutions globally.

What Are Latest Mergers And Acquisitions In The Endocrinology Drugs Market?

In July 2024, AstraZeneca, a UK-based pharmaceutical company, acquired Amolyt Pharma Inc. for an undisclosed amount. With this acquisition, AstraZeneca aims to strengthen its portfolio in rare endocrine diseases by integrating Amolyt Pharma's innovative pipeline of late-stage therapies. Amolyt Pharma Inc. is a France-based pharmaceutical company specializing in developing therapies for rare endocrine diseases.

Regional Insights

North America was the largest region in the endocrinology drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Endocrinology Drugs Market?

The endocrinology drugs market consists of sales of insulin analogs, antithyroid drugs, and anti-diabetic drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Endocrinology Drugs Market Report 2026?

The endocrinology drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the endocrinology drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.